News Roundup this Week

• Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access: Eli Lilly has announced a price reduction for its higher-dose vials of Zepbound, aiming to attract individuals without insurance coverage. This move comes as the FDA declares the tirzepatide shortage resolved, impacting the availability of compounded versions.https://www.cnbc.com/2025/02/25/eli-lilly-offering-more-cheaper-vials-of-zepbound-weight-loss-drug.html

• Drug Compounders sue FDA over removal of Wegovy, Ozempic from shortage list: https://www.reuters.com/business/healthcare-pharmaceuticals/drug-compounders-sue-us-fda-over-removal-wegovy-ozempic-shortage-list-2025-02-24/ 

• Independent Pharmacists Advocate for PBM Reform: Independent pharmacists in Mississippi are urging legislators to pass a bill increasing regulation and transparency of pharmacy benefit managers (PBMs). They claim that current PBM practices threaten the viability of independent pharmacies and limit patient access to services. https://mississippitoday.org/2025/02/27/independent-pharmacists-urge-legislators-to-pass-pharmacy-benefit-manager-reform-bill/

• The global compounding pharmacy market is projected to grow significantly, driven by demand for personalized medicine, with a forecasted value of over $26 billion by 2034, according to a Transparency Market Research report https://www.transparencymarketresearch.com/compounding-pharmacy-market-insights.html

Featured Compounding Formula

Featured Blog Post

Thank you